Intellivax Overview

  • Founded
  • 1997
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $15.6M
Latest Deal Amount

Intellivax General Information

Description

Developer of vaccines and other therapeutic products that provide mucosal and systemic protection. The company offers nasal vaccine against shigella, a bacteria that causes dysentery and diarrhea.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 7150 Frederick Banting
  • Suite 200
  • Saint Laurent, Quebec H4S 2A1
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intellivax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 16-May-2001 $15.6M 00.000 000.00 Completed Startup
1. Early Stage VC 00.000 00.000 Completed Startup
To view Intellivax’s complete valuation and funding history, request access »

Intellivax Executive Team (1)

Name Title Board Seat Contact Info
William Milligan Chief Executive Officer & Director
To view Intellivax’s complete executive team members history, request access »

Intellivax Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Maryland Health Care Product Development Corporate Venture Capital Minority 000 0000 000000 0
Société Innovatech du Grand Montréal Venture Capital Minority 000 0000 000000 0
To view Intellivax’s complete investors history, request access »